Moliterno D J, Mukherjee D
Department of Cardiology, The Cleveland Clinic Foundation, OH 44195, USA.
Am Heart J. 2000 Dec;140(6 Suppl):S136-42. doi: 10.1067/mhj.2000.111608.
With the addition of more potent antiplatelet and antithrombin therapies to the armamentarium of the treatment of acute coronary syndromes and percutaneous coronary interventions, monitoring these therapies has become an important interest. Current and evolving technologies to monitor the extent of inhibition of platelet aggregation and activity of factor Xa caused by IIb/IIIa antagonists and low-molecular-weight heparin, respectively, will be covered in this overview. An underlying question to be considered is whether the results generated from monitoring will effect a change that will improve the efficacy (prevent thrombotic events) or reduce adverse events (bleeding) from these potent therapies.
随着更有效的抗血小板和抗凝血酶疗法被纳入急性冠状动脉综合征和经皮冠状动脉介入治疗的手段中，对这些疗法进行监测已成为一项重要的关注点。本综述将涵盖目前以及不断发展的技术，这些技术分别用于监测由IIb/IIIa拮抗剂和低分子量肝素所引起的血小板聚集抑制程度以及Xa因子的活性。一个需要考虑的潜在问题是，监测所产生的结果是否会带来变化，从而提高这些强效疗法的疗效（预防血栓形成事件）或减少不良事件（出血）。
